JDD December 2025 Issue Highlights | Special Focus: Immunodermatology

We’re closing out 2025 with an immunodermatology–focused issue of the Journal of Drugs in Dermatology. From incretin-based therapies for hidradenitis suppurativa (HS) to real-world data on cardiometabolic risk in inflammatory skin disease, these Editor’s Picks connect skin and systemic health with practical pearls for clinic.

• • GLP-1 Receptor Agonists in Hidradenitis Suppurativa: A Novel Therapeutic Approach for Hidradenitis Suppurativa and Its Comorbidities
    Why it matters: A timely review of emerging evidence that GLP‑1RAs may reduce HS activity while improving metabolic comorbidities.

• • An Open-Label, Single-Center Proof of Concept Study Evaluating the Efficacy and Safety of Tirzepatide for Moderate to Severe Hidradenitis Suppurativa
    Why it matters: Early data suggest dual incretin agonism (GIP/GLP‑1) is promising for HS with obesity; larger controlled trials are warranted.

• • Evaluating the Risk of Atherosclerotic Cardiovascular Disease in Inflammatory Skin Disease: Insights From a TriNetX Cohort Study
    Why it matters: Reinforces inflammatory skin disease as a marker of systemic inflammation and elevated ASCVD risk. Highlighted twice by the editor.

• • Isotretinoin Does Not Increase the Risk of Inflammatory Bowel Disease: A TriNetX Retrospective Cohort Analysis
    Why it matters: Real-world evidence does not support an increased IBD risk with isotretinoin—useful for patient counseling.

• • Clindamycin Phosphate 1.2%/Adapalene 0.15%/Benzoyl Peroxide 3.1% Gel for Moderate-to-Severe Acne: A Pooled Analysis by Age
    Why it matters: Pooled analyses of the only approved fixed‑dose triple topical show efficacy and tolerability across age groups.

• • Skin Improvements in Acne Vulgaris Patients Using Gel-Matrix Moisturizer as a Complement to Topical Treatments
    Why it matters: Barrier-supportive care can reduce irritation and support adherence during acne therapy.

• • Clinical Evaluation of Thiamidol-Containing Formulations for the Visual Management of Facial Hyperpigmentation
    Why it matters: Clinical data support thiamidol-containing regimens as part of comprehensive hyperpigmentation management.

• • The Current Landscape of Treatment of Warts
    Why it matters: A practical review that underscores the need for larger, contemporary trials to refine evidence-based wart care.

• • Report From the 2024 International Dermatology Outcome Measures (IDEOM) Annual Meeting
    Why it matters: Key outcome-measure advances across psoriatic disease, HS, connective tissue disease, vitiligo, itch, AK, acne, and CTCL.

• • Resolution of Lichen Simplex Chronicus With Nemolizumab: A Case Report
    Why it matters: Highlights the potential of IL‑31–targeted therapy for refractory chronic itch disorders.

• • Disparities in Hidradenitis Suppurativa Clinical Trials: An Updated Review of ClinicalTrials.gov from 2020 to 2024
    Why it matters: Calls attention to persistent demographic and access disparities in HS trials—and the need for inclusive study design.

Bottom line for your clinic:

• • Think systemically: Screen for cardiometabolic risk in chronic inflammatory skin disease.
  • Leverage the immunometabolic axis: Incretin-based strategies show promise in HS—track the data and connect patients to trials.
  • Reassure when the data allow: Current real-world evidence does not support an IBD signal with isotretinoin.
  • Optimize adherence: Barrier-supportive skincare boosts tolerability and outcomes in acne regimens.
  • Advance equity: Encourage diverse enrollment and reduce barriers to participation in HS research.

Did you enjoy this article? Find more JDD Highlights here.